Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

ISG20, an actor of the innate immune response.

Degols G, Eldin P, Mechti N.

Biochimie. 2007 Jun-Jul;89(6-7):831-5. Epub 2007 Mar 15.

PMID:
17445960
2.

The exonuclease ISG20 mainly localizes in the nucleolus and the Cajal (Coiled) bodies and is associated with nuclear SMN protein-containing complexes.

Espert L, Eldin P, Gongora C, Bayard B, Harper F, Chelbi-Alix MK, Bertrand E, Degols G, Mechti N.

J Cell Biochem. 2006 Aug 1;98(5):1320-33.

PMID:
16514659
3.

Fertilization regulates apoptosis of Ciona intestinalis extra-embryonic cells through thyroxine (T4)-dependent NF-kappaB pathway activation during early embryonic development.

Maury B, Martinand-Mari C, Chambon JP, Soulé J, Degols G, Sahuquet A, Weill M, Berthomieu A, Fort P, Mangeat P, Baghdiguian S.

Dev Biol. 2006 Jan 1;289(1):152-65. Epub 2005 Nov 28.

4.

Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1.

Espert L, Degols G, Lin YL, Vincent T, Benkirane M, Mechti N.

J Gen Virol. 2005 Aug;86(Pt 8):2221-9.

PMID:
16033969
5.

The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappaB and IRF1 activation.

Espert L, Rey C, Gonzalez L, Degols G, Chelbi-Alix MK, Mechti N, Gongora C.

Oncogene. 2004 Jun 3;23(26):4636-40.

PMID:
15064705
6.

ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses.

Espert L, Degols G, Gongora C, Blondel D, Williams BR, Silverman RH, Mechti N.

J Biol Chem. 2003 May 2;278(18):16151-8. Epub 2003 Feb 19.

7.

A unique ISRE, in the TATA-less human Isg20 promoter, confers IRF-1-mediated responsiveness to both interferon type I and type II.

Gongora C, Degols G, Espert L, Hua TD, Mechti N.

Nucleic Acids Res. 2000 Jun 15;28(12):2333-41.

10.
11.

Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells.

Bordier B, Perala-Heape M, Degols G, Lebleu B, Litvak S, Sarih-Cottin L, Hélène C.

Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9383-7.

12.

Reversible inhibition of gene expression by a psoralen functionalized triple helix forming oligonucleotide in intact cells.

Degols G, Clarenc JP, Lebleu B, Léonetti JP.

J Biol Chem. 1994 Jun 17;269(24):16933-7.

13.

Oligonucleotide-poly(L-lysine)-heparin complexes: potent sequence-specific inhibitors of HIV-1 infection.

Degols G, Devaux C, Lebleu B.

Bioconjug Chem. 1994 Jan-Feb;5(1):8-13.

PMID:
8199237
14.

Inhibition of HIV-1 replication in cultured cells with phosphorylated dideoxyuridine derivatives encapsulated in immunoliposomes.

Zelphati O, Degols G, Loughrey H, Leserman L, Pompon A, Puech F, Maggio AF, Imbach JL, Gosselin G.

Antiviral Res. 1993 Jul;21(3):181-95.

PMID:
8215297
15.

Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation.

Clarenc JP, Degols G, Leonetti JP, Milhaud P, Lebleu B.

Anticancer Drug Des. 1993 Feb;8(1):81-94. Review. No abstract available.

PMID:
8476504
16.

Comparative evaluation of seven oligonucleotide analogues as potential antisense agents.

Morvan F, Porumb H, Degols G, Lefebvre I, Pompon A, Sproat BS, Rayner B, Malvy C, Lebleu B, Imbach JL.

J Med Chem. 1993 Jan 22;36(2):280-7.

PMID:
8423598
17.

Cell delivery and mechanisms of action of antisense oligonucleotides.

Leonetti JP, Degols G, Clarenc JP, Mechti N, Lebleu B.

Prog Nucleic Acid Res Mol Biol. 1993;44:143-66. Review. No abstract available.

PMID:
8434122
18.

Sequence-specific activity of antisense oligonucleotides conjugated to poly (L-lysine) carriers.

Degols G, Leonetti JP, Lebleu B.

Ann N Y Acad Sci. 1992 Oct 28;660:331-3. No abstract available.

PMID:
1340150
19.

Antisense inhibitors of HIV: problems and perspectives.

Degols G, Leonetti JP, Milhaud P, Mechti N, Lebleu B.

Antiviral Res. 1992 Apr;17(4):279-87. Review. No abstract available.

PMID:
1642480
20.
21.

[Control of gene expression by antisense nucleic acids].

Lebleu B, Clarenc JP, Degols G, Leonetti JP, Milhaud P.

C R Seances Soc Biol Fil. 1992;186(5):560-6. Review. French.

PMID:
1305901
22.

Poly(L-lysine)-conjugated oligonucleotides promote sequence-specific inhibition of acute HIV-1 infection.

Degols G, Leonetti JP, Benkirane M, Devaux C, Lebleu B.

Antisense Res Dev. 1992 Winter;2(4):293-301.

PMID:
1284042
23.

Intracellular distribution of microinjected antisense oligonucleotides.

Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B.

Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2702-6.

24.

Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene.

Degols G, Leonetti JP, Mechti N, Lebleu B.

Nucleic Acids Res. 1991 Feb 25;19(4):945-8.

25.

Nuclear location of synthetic oligonucleotides microinjected somatic cells: its implication in an antisense strategy.

Mechti N, Leonetti JP, Clarenc JP, Degols G, Lebleu B.

Nucleic Acids Symp Ser. 1991;(24):147-50.

PMID:
1668686
26.

Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication.

Leonetti JP, Machy P, Degols G, Lebleu B, Leserman L.

Proc Natl Acad Sci U S A. 1990 Apr;87(7):2448-51.

27.

Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake.

Leonetti JP, Degols G, Lebleu B.

Bioconjug Chem. 1990 Mar-Apr;1(2):149-53.

PMID:
1965625
28.

Targeted liposomes and intracellular delivery of macromolecules.

Leserman L, Machy P, Leonetti JP, Milhaud PG, Degols G, Lebleu B.

Prog Clin Biol Res. 1990;343:95-102. Review. No abstract available.

PMID:
2198587
29.

Supplemental Content

Loading ...
Support Center